On June 3, 2024 Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for a broad range of immunological diseases and cancer, reported that clinical data for its lead drug candidate, ELA026, will be presented as one of six selected abstracts in a late-breaking oral session at the European Hematology Association (EHA) (Free EHA Whitepaper) Congress (Press release, Electra Therapeutics, JUN 3, 2024, View Source [SID1234644004]). The conference is being held in Madrid, Spain and live-streamed on June 13-16, 2024.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The oral presentation will describe clinical data from a Phase 1b study of ELA026 for the treatment of secondary hemophagocytic lymphohistiocytosis (sHLH), a rare, life-threatening hyperinflammatory disease for which there is currently no approved treatment. ELA026 is a monoclonal antibody that targets signal regulatory protein (SIRP)-α/β1/γ, enabling precise depletion of pathologic immune cells. The abstract is published on the EHA (Free EHA Whitepaper) website here.
Details of the oral presentation are as follows:
Title: ELA026 Targeting of SIRP(+) Immune Cells Results in a High Response Rate and Improved 2-Month Survival of Treatment-Naïve Malignancy-Associated Hemophagocytic Lymphohistiocytosis in a Phase 1 Study
Presenter: Abhishek Maiti, MD, Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center
Session Name: Late-Breaking Oral Session
Session Date & Time: Sunday, June 16, 2024, 9:45 – 11:15 a.m. Central European Summer Time
Location: Madrid Recinto Ferial Hall Picasso, and livestreamed on the EHA (Free EHA Whitepaper) Congress platform
Abstract Code: LB3442
About Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Secondary hemophagocytic lymphohistiocytosis (sHLH) is a rare, life-threatening inflammatory disease for which there is no approved treatment. It can be triggered by cancer (malignancy-associated HLH, or mHLH), infection, autoimmune disease, or immunotherapy. sHLH is associated with a systemic inflammatory response for which patients require immediate intervention. Without treatment, patients may experience multiple organ failure and death. sHLH has a high mortality rate during the first months of diagnosis, with mHLH patients having the poorest outcomes.